BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
BioNTech SE (Nasdaq: BNTX) has announced it will release its first quarter 2025 financial results on Monday, May 5, 2025. The company will host a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss the financial results and provide a corporate update.
Investors, financial analysts, and the public can access the conference call via telephone by registering through a provided link, which will supply dial-in numbers and a PIN. Registration is recommended at least one day in advance. The webcast and slide presentation will be accessible through the company's Investor Relations section, with a replay available for 30 days after the call.
BioNTech SE (Nasdaq: BNTX) ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 lunedì 5 maggio 2025. La società terrà una conference call e una webcast alle 8:00 a.m. EDT (14:00 CEST) per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Investitori, analisti finanziari e pubblico potranno partecipare alla conference call telefonicamente iscrivendosi tramite un link fornito, che fornirà i numeri di accesso e un PIN. Si consiglia di registrarsi almeno un giorno prima. La webcast e la presentazione delle slide saranno disponibili nella sezione Investor Relations dell’azienda, con una replica accessibile per 30 giorni dopo la chiamata.
BioNTech SE (Nasdaq: BNTX) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el lunes 5 de mayo de 2025. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 8:00 a.m. EDT (2:00 p.m. CEST) para discutir los resultados financieros y ofrecer una actualización corporativa.
Inversionistas, analistas financieros y el público podrán acceder a la conferencia telefónica registrándose a través de un enlace proporcionado, que incluirá números de acceso y un PIN. Se recomienda registrarse al menos un día antes. La transmisión en vivo y la presentación de diapositivas estarán disponibles en la sección de Relaciones con Inversionistas de la empresa, con una repetición accesible durante 30 días después de la llamada.
BioNTech SE (나스닥: BNTX)는 2025년 5월 5일 월요일에 2025년 1분기 재무 결과를 발표할 예정입니다. 회사는 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 동부 표준시 오전 8시(중앙유럽 여름시간 오후 2시)에 컨퍼런스 콜과 웹캐스트를 진행합니다.
투자자, 금융 분석가 및 일반인은 제공된 링크를 통해 등록하여 전화로 컨퍼런스 콜에 참여할 수 있으며, 등록 시 전화 접속 번호와 PIN이 제공됩니다. 최소 하루 전에 등록하는 것이 권장됩니다. 웹캐스트와 슬라이드 프레젠테이션은 회사의 투자자 관계 섹션에서 접속 가능하며, 콜 이후 30일간 다시보기 서비스가 제공됩니다.
BioNTech SE (Nasdaq : BNTX) a annoncé qu’elle publiera ses résultats financiers du premier trimestre 2025 le lundi 5 mai 2025. La société organisera une conférence téléphonique et une webdiffusion à 8h00 EDT (14h00 CEST) pour discuter des résultats financiers et fournir une mise à jour d’entreprise.
Les investisseurs, analystes financiers et le public pourront accéder à la conférence téléphonique par téléphone en s’inscrivant via un lien fourni, qui donnera les numéros d’accès et un code PIN. Il est recommandé de s’inscrire au moins un jour à l’avance. La webdiffusion et la présentation des diapositives seront disponibles dans la section Relations Investisseurs de la société, avec un replay accessible pendant 30 jours après l’appel.
BioNTech SE (Nasdaq: BNTX) hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Montag, den 5. Mai 2025, zu veröffentlichen. Das Unternehmen wird um 8:00 Uhr EDT (14:00 Uhr MESZ) eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren, Finanzanalysten und die Öffentlichkeit können über einen bereitgestellten Link, der Einwahlnummern und eine PIN enthält, telefonisch an der Telefonkonferenz teilnehmen. Eine Registrierung mindestens einen Tag im Voraus wird empfohlen. Der Webcast und die Präsentation stehen im Investor-Relations-Bereich des Unternehmens zur Verfügung, mit einer Wiedergabe, die 30 Tage nach der Telefonkonferenz abrufbar ist.
- None.
- None.
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancers includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Michael Horowicz
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
FAQ
When will BioNTech (BNTX) release Q1 2025 earnings?
What time is BioNTech's (BNTX) Q1 2025 earnings call?
How can investors access BioNTech's (BNTX) Q1 2025 earnings call?
How long will BioNTech's (BNTX) Q1 2025 earnings call replay be available?
